Elsevier Launches New Journal: Multiple Sclerosis And Related Disorders
London, UK, 8 June, 2011 – Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, is pleased to announce the launch of a new journal, Multiple Sclerosis and Related Disorders with its first issue publication in January 2012. Published quarterly, complimentary print copies of the advance issue of the journal will be available at the 5th Joint Triennial Congress of the European and American Committees for Treatment and Research in Multiple Sclerosis, to take place in in Amsterdam, the Netherlands, 19–22 October 2011.
Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disordersis a wide ranging international journal supported by key researchers from all neuroscience domains that focus on Multiple Sclerosis and associated disease of the nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues.
The journal Multiple Sclerosis and Related Disorders (MSARD) will be mostly web based with the ultimate aim of web and e-reader only versions, save for institutional subscribers that may wish to have a shelf copy. MSARD will have a journal club, an associated Wiki and Twitter account to create an MS community and include an RSS feed. A special section will be created to provide timely information on key discoveries written for a lay audience- a resource accessible by the public and suited for physicians who wish to provide patients with information.
The Journal’s Chief Editorsare: Professor Gavin Giovannoni PhD, FCP, FRCP, FRCPath. Lead, Centre for Neuroscience and Trauma,Barts and The London School of Medicine and Dentistry; Professor Christopher H. Hawkes MD FRCP. Honorary Professor of Neurology, Centre for Neuroscience and Trauma, Barts and The London School of Medicine and Dentistry; Professor Fred D. Lublin, MD, Saunders Family Professor of Neurology, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York; and, Dr Brenda Banwell MD. Department of Pediatrics, Division of Neurology, The Hospital for Sick Children, University of Toronto.
The team of chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.
The first, advance issue of the Multiple Sclerosis and Related Disorders will be freely available online on SciVerse ScienceDirect and Elsevier Health Advance during the 4th quarter of 2011.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and 25,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
+44 20 7424 4302